CMTx Biotech successfully submitted a Clinical Trial Planning grant application to the National Center for Advancing Translational Sciences (NCATS) this week requesting financial support to design a Phase II clinical study evaluating the safety and efficacy of the company’s lead drug candidate, incyclinide (CMT-3 / COL-3), in hospitalized COVID-19 patients. The company also proposed to engage the U.S. Food and Drug Administration (FDA) in a pre-IND meeting, as well as to prepare and submit an Investigational New Drug (IND) application. Special thanks to our clinical collaborators, Dr. Sharon nachman (Stony Brook University) and Dr. Hani Aiash (SUNY Upstate Medical University), as well as Chris Czura, PhD, Jo Ann Zbur Wilson, Janet S Lee, PhD, Ashley Holub, Daniel Keene, James Keane, MBA, Joseph Scaduto and Andy Protter for their contributions to the written proposal.
https://lnkd.in/d8AKsHS